Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DECITABINE vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Decitabine is a hypomethylating agent that incorporates into DNA, inhibiting DNA methyltransferase, leading to DNA hypomethylation and reactivation of silenced genes, thereby restoring normal growth control and differentiation in hematopoietic cells.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
FDA-approved: Treatment of patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).,Off-label: Treatment of acute myeloid leukemia (AML), particularly in older adults not fit for intensive chemotherapy.
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
Decitabine 15 mg/m² intravenously over 3 hours every 8 hours for 3 days, repeated every 6 weeks for myelodysplastic syndromes.
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal half-life: 0.5-1.5 hours. Short half-life; administered over 1 hour IV to maintain cytotoxic levels.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
Decitabine is primarily metabolized via deamination by cytidine deaminase in the liver and other tissues. It is not extensively metabolized by cytochrome P450 enzymes.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Renal: 45% as unchanged drug; biliary/fecal: negligible (<5%). Hepatic metabolism accounts for remainder.
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
30-40% bound, primarily to albumin.
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
Vd: 20-40 L/kg (extensive tissue distribution, including CNS).
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
IV: 100%; oral: not clinically relevant (<10% due to deamination).
Intravenous administration yields 100% bioavailability.
No specific dose adjustment recommended for GFR ≥30 m L/min. Insufficient data for GFR <30 m L/min. Monitor renal function and use caution.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
No dose adjustment specified for Child-Pugh Class A or B. For Child-Pugh Class C, use is not recommended due to lack of data. Monitor hepatic function.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Safety and efficacy not established in pediatric patients. Dosing not defined.
Safety and effectiveness in pediatric patients have not been established.
No specific dose adjustment. Monitor for increased toxicity, especially myelosuppression, in elderly patients with impaired organ function.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
Decitabine should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Myelosuppression and worsening neutropenia may occur. Monitor complete blood counts frequently. There is no known safe level of exposure in pregnancy; women of childbearing potential should be advised to avoid pregnancy during treatment.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Myelosuppression: Neutropenia, thrombocytopenia, and anemia may worsen during treatment; monitor blood counts regularly.,Hepatotoxicity: Elevations of liver enzymes and bilirubin have been reported; monitor hepatic function.,Renal toxicity: Serum creatinine elevations may occur; monitor renal function.,Fetal harm: Can cause fetal harm; advise contraception in women of reproductive potential and avoid pregnancy during treatment.,Tumor lysis syndrome: May occur; ensure adequate hydration and monitor uric acid levels.,Infusion reactions: Hypersensitivity reactions including rash, urticaria, and dyspnea have been reported.
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
Hypersensitivity to decitabine or any component of the formulation.,Breastfeeding: Not recommended due to potential for serious adverse reactions in nursing infants.,Pregnancy: Should not be used in pregnant women or those planning pregnancy due to risk of fetal harm.
None known.
No known food interactions. Avoid grapefruit and grapefruit juice as a general precaution due to potential CYP3A4 interaction, though not specifically studied with decitabine. Maintain adequate hydration.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
Decitabine is teratogenic in animals and has the potential to cause fetal harm in humans. In first trimester, there is a high risk of major malformations and fetal death. Second and third trimester exposure may cause growth restriction, myelosuppression, and neurodevelopmental effects. Use contraindicated in pregnancy unless benefit outweighs risk.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
No data on presence in human milk. Due to potential for serious adverse reactions in breastfed infants (e.g., myelosuppression, carcinogenesis), breastfeeding is contraindicated during therapy and for at least 2 weeks after last dose. M/P ratio unknown.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
No specific dosing adjustment guidelines exist for pregnant patients. Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance, but no data on required dose modifications. Use lowest effective dose if unavoidable, and monitor for toxicity. Consider alternative agents.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
Administer decitabine via IV infusion over 1 hour. Premedicate with antiemetics. Monitor CBC, LFTs, and serum creatinine prior to each cycle. Consider growth factor support for neutropenia. Avoid live vaccines during treatment. Dose adjustment required for renal impairment (Cr Cl < 30 m L/min). Not a vesicant; use central line not mandatory. Synergy with histone deacetylase inhibitors is under investigation. Hypersensitivity reactions (e.g., rash, urticaria) may occur.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
Take anti-nausea medication as prescribed before infusion.,Report any signs of infection such as fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, flu nasal spray) while on this medication.,Use effective contraception during treatment and for at least 6 months after.,You may experience fatigue; plan rest periods and avoid driving if drowsy.,Stay well hydrated to reduce risk of kidney problems.,Rarely, you may have a severe allergic reaction; seek emergency help for hives, difficulty breathing, or swelling.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
"Decitabine may decrease the cardiotoxic activities of Digitoxin."
"Decitabine may decrease the cardiotoxic activities of Deslanoside."
"The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Decitabine."
No interactions on record
Common clinical questions about DECITABINE vs COLUMVI, answered by our medical review team.
DECITABINE is a Antineoplastic Agent (DNA Demethylating Agent) that works by Decitabine is a hypomethylating agent that incorporates into DNA, inhibiting DNA methyltransferase, leading to DNA hypomethylation and reactivation of silenced genes, thereby restoring normal growth control and differentiation in hematopoietic cells.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DECITABINE and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DECITABINE is: Decitabine 15 mg/m² intravenously over 3 hours every 8 hours for 3 days, repeated every 6 weeks for myelodysplastic syndromes.. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DECITABINE and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DECITABINE is classified as Category C. Decitabine is teratogenic in animals and has the potential to cause fetal harm in humans. In first trimester, there is a high risk of major malformations and fetal death. Second an. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.